REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency CONSUMER HEALTH SEGMENT (2) OTC US 633 $ 543 16.8% 16.8% - 2,594 $ 2,460 5.4% 5.4% - Intl 740 642 15.1% 14.9% 0.2% 2,634 2,364 11.4% 6.9% 4.5% WW 1,373 1,185 15.9% 15.8% 0.1% 5,227 4,824 8.4% 6.2% 2.2% SKIN HEALTH / BEAUTY US 538 583 -7.8% -7.8% - 2,400 2,350 2.1% 2.1% - Intl 546 594 -8.2% -6.4% -1.8% 2,141 2,100 1.9% -0.3% 2.2% WW 1,084 1,177 -8.0% -7.1% -0.9% 4,541 4,450 2.0% 1.0% 1.0% ORAL CARE US 159 173 -8.2% -8.2% - 637 683 -6.7% -6.7% - Intl 246 264 -7.2% -5.5% -1.7% 1,008 958 5.1% 2.8% 2.3% WW 405 437 -7.6% -6.5% -1.1% 1,645 1,641 0.2% -1.2% 1.4% BABY CARE US 90 97 -7.5% -7.5% - 378 376 0.5% 0.5% - Intl 309 310 -0.3% 1.3% -1.6% 1,188 1,141 4.1% 3.7% 0.4% WW 399 407 -2.0% -0.8% -1.2% 1,566 1,517 3.2% 2.9% 0.3% WOMEN'S HEALTH US 4 3 14.1% 14.1% - 13 13 -1.6% -1.6% - Intl 230 234 -1.8% 1.2% -3.0% 905 888 1.8% 2.0% -0.2% WW 233 237 -1.6% 1.3% -2.9% 917 901 1.8% 1.9% -0.1% WOUND CARE / OTHER US 106 110 -4.2% -4.2% - 495 480 3.1% 3.1% - Intl 57 65 -9.6% -10.2% 0.6% 243 240 1.7% -2.7% 4.4% WW 164 175 -6.2% -6.4% 0.2% 739 720 2.6% 1.2% 1.4% TOTAL CONSUMER HEALTH US 1,529 1,509 1.3% 1.3% - 6,516 6,362 2.4% 2.4% - Intl 2,128 2,109 0.9% 2.1% -1.2% 8,119 7,691 5.6% 3.1% 2.5% WW 3,657 $ 3,618 1.1% 1.8% -0.7% 14,635 $ 14,053 4.1% 2.8% 1.3% See footnotes at end of schedule % Change % Change -- 1 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS PHARMACEUTICAL SEGMENT (2,3) 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency IMMUNOLOGY US 2,912 $ 2,845 2.4% 2.4% - 10,843 $ 10,175 6.6% 6.6% - Intl 1,443 1,261 14.5% 17.9% -3.4% 5,907 4,880 21.0% 17.7% 3.3% WW 4,355 4,105 6.1% 7.1% -1.0% 16,750 15,055 11.3% 10.2% 1.1% REMICADE US 511 656 -22.2% -22.2% - 2,019 2,508 -19.5% -19.5% - US Exports (4) 39 25 53.5% 53.5% - 236 346 -31.9% -31.9% - Intl 214 220 -2.3% -2.4% 0.1% 935 893 4.8% 0.4% 4.4% WW 764 901 -15.2% -15.2% 0.0% 3,190 3,747 -14.9% -15.9% 1.0% SIMPONI / SIMPONI ARIA US 287 315 -8.9% -8.9% - 1,127 1,155 -2.4% -2.4% - Intl 271 261 3.6% 8.4% -4.8% 1,148 1,088 5.5% 4.1% 1.4% WW 559 576 -3.2% -1.0% -2.2% 2,276 2,243 1.4% 0.8% 0.6% STELARA US 1,542 1,572 -1.9% -1.9% - 5,938 5,240 13.3% 13.3% - Intl 792 672 17.9% 21.7% -3.8% 3,196 2,467 29.6% 25.9% 3.7% WW 2,334 2,244 4.0% 5.1% -1.1% 9,134 7,707 18.5% 17.3% 1.2% TREMFYA US 528 276 90.9% 90.9% - 1,503 926 62.3% 62.3% - Intl 165 105 56.9% 61.8% -4.9% 624 421 48.2% 44.0% 4.2% WW 693 382 81.5% 82.8% -1.3% 2,127 1,347 57.9% 56.5% 1.4% OTHER IMMUNOLOGY US 6 - * * - 21 - * * - Intl 0 2 * * * 3 11 -73.3% -74.6% 1.3% WW 6 2 * * * 24 11 * * * INFECTIOUS DISEASES US 614 470 30.8% 30.8% - 2,249 1,735 29.7% 29.7% - Intl 1,824 442 * * -3.0% 3,612 1,839 96.3% 93.4% 2.9% WW 2,437 912 * * -1.5% 5,861 3,574 64.0% 62.5% 1.5% COVID-19 VACCINE US 213 - * * - 634 - * * - Intl 1,405 - * * - 1,751 - * * - WW 1,619 - * * - 2,385 - * * - EDURANT / rilpivirine US 10 11 -15.8% -15.8% - 41 44 -7.6% -7.6% - Intl 220 236 -6.8% -3.3% -3.5% 953 920 3.6% 0.4% 3.2% WW 230 248 -7.2% -3.9% -3.3% 994 964 3.1% 0.0% 3.1% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 380 433 -12.2% -12.2% - 1,508 1,587 -4.9% -4.9% - Intl 135 136 -0.1% 3.0% -3.1% 575 597 -3.6% -6.0% 2.4% WW 515 569 -9.3% -8.5% -0.8% 2,083 2,184 -4.6% -5.2% 0.6% OTHER INFECTIOUS DISEASES US 11 25 -55.9% -55.9% - 66 104 -36.0% -36.0% - Intl 63 71 -10.9% -10.0% -0.9% 333 323 3.0% -0.1% 3.1% WW 74 96 -22.9% -22.2% -0.7% 399 427 -6.5% -8.9% 2.4% % Change % Change -- 2 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency NEUROSCIENCE US 899 806 11.4% 11.4% - 3,347 3,091 8.3% 8.3% - Intl 894 892 0.2% 3.2% -3.0% 3,664 3,457 6.0% 3.9% 2.1% WW 1,793 1,698 5.5% 7.1% -1.6% 7,011 6,548 7.1% 5.9% 1.2% CONCERTA / Methylphenidate US 55 33 68.1% 68.1% - 172 183 -5.8% -5.8% - Intl 123 120 3.2% 6.0% -2.8% 495 439 12.8% 10.1% 2.7% WW 178 153 17.2% 19.4% -2.2% 667 622 7.3% 5.4% 1.9% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 668 610 9.5% 9.5% - 2,550 2,314 10.2% 10.2% - Intl 361 355 1.5% 5.0% -3.5% 1,472 1,339 10.0% 6.9% 3.1% WW 1,029 965 6.5% 7.8% -1.3% 4,022 3,653 10.1% 9.0% 1.1% RISPERDAL CONSTA US 77 76 2.3% 2.3% - 287 296 -2.9% -2.9% - Intl 63 92 -30.3% -26.4% -3.9% 305 346 -11.8% -13.1% 1.3% WW 140 167 -15.6% -13.4% -2.2% 592 642 -7.7% -8.4% 0.7% OTHER NEUROSCIENCE US 99 88 11.7% 11.7% - 338 298 13.3% 13.3% - Intl 346 326 6.2% 8.6% -2.4% 1,391 1,334 4.3% 3.2% 1.1% WW 445 414 7.4% 9.2% -1.8% 1,729 1,632 6.0% 5.0% 1.0% ONCOLOGY US 1,594 1,469 8.5% 8.5% - 5,958 5,092 17.0% 17.0% - Intl 2,184 1,965 11.1% 15.2% -4.1% 8,590 7,275 18.1% 15.3% 2.8% WW 3,778 3,434 10.0% 12.3% -2.3% 14,548 12,367 17.6% 16.0% 1.6% DARZALEX US 867 692 25.3% 25.3% - 3,169 2,232 42.0% 42.0% - Intl 778 561 38.9% 43.5% -4.6% 2,854 1,958 45.8% 42.6% 3.2% WW 1,645 1,253 31.4% 33.4% -2.0% 6,023 4,190 43.8% 42.3% 1.5% ERLEADA US 235 176 33.4% 33.4% - 813 583 39.3% 39.3% - Intl 149 64 * * * 478 176 * * * WW 384 241 59.8% 61.3% -1.5% 1,291 760 70.0% 68.7% 1.3% IMBRUVICA US 436 492 -11.3% -11.3% - 1,747 1,821 -4.0% -4.0% - Intl 626 625 0.0% 3.4% -3.4% 2,622 2,307 13.6% 10.4% 3.2% WW 1,062 1,117 -5.0% -3.1% -1.9% 4,369 4,128 5.8% 4.1% 1.7% ZYTIGA / abiraterone acetate US 23 89 -74.2% -74.2% - 119 373 -68.1% -68.1% - Intl 525 533 -1.4% 3.1% -4.5% 2,178 2,097 3.9% 1.5% 2.4% WW 548 622 -11.8% -7.9% -3.9% 2,297 2,470 -7.0% -9.0% 2.0% OTHER ONCOLOGY US 34 20 64.7% 64.7% - 110 83 31.7% 31.7% - Intl 106 183 -42.0% -39.2% -2.8% 458 738 -37.9% -38.7% 0.8% WW 140 202 -31.3% -28.8% -2.5% 568 821 -30.8% -31.5% 0.7% % Change % Change -- 3 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency PULMONARY HYPERTENSION US 587 592 -0.7% -0.7% - 2,365 2,133 10.9% 10.9% - Intl 264 273 -3.6% 0.8% -4.4% 1,085 1,015 6.9% 5.5% 1.4% WW 851 865 -1.6% -0.2% -1.4% 3,450 3,148 9.6% 9.2% 0.4% OPSUMIT US 286 279 2.0% 2.0% - 1,147 1,008 13.7% 13.7% - Intl 162 173 -6.1% -1.7% -4.4% 672 631 6.6% 5.1% 1.5% WW 448 452 -1.1% 0.6% -1.7% 1,819 1,639 11.0% 10.4% 0.6% UPTRAVI US 264 263 0.0% 0.0% - 1,056 955 10.5% 10.5% - Intl 46 38 21.9% 24.7% -2.8% 181 138 31.1% 27.0% 4.1% WW 310 301 2.7% 3.1% -0.4% 1,237 1,093 13.1% 12.6% 0.5% OTHER PULMONARY HYPERTENSION US 38 49 -20.1% -20.1% - 163 169 -3.7% -3.7% - Intl 56 63 -12.2% -6.6% -5.6% 232 247 -5.9% -5.4% -0.5% WW 94 112 -15.6% -12.4% -3.2% 395 416 -5.0% -4.7% -0.3% CARDIOVASCULAR / METABOLISM / OTHER US 813 935 -13.1% -13.1% - 3,192 3,509 -9.0% -9.0% - Intl 261 317 -17.8% -16.0% -1.8% 1,268 1,369 -7.4% -10.9% 3.5% WW 1,074 1,253 -14.3% -13.8% -0.5% 4,460 4,878 -8.6% -9.6% 1.0% XARELTO US 644 629 2.5% 2.5% - 2,438 2,345 4.0% 4.0% - Intl - - - - - - - - - - WW 644 629 2.5% 2.5% - 2,438 2,345 4.0% 4.0% - INVOKANA / INVOKAMET US 59 159 -63.1% -63.1% - 308 564 -45.4% -45.4% - Intl 60 58 3.8% 4.5% -0.7% 254 231 9.9% 5.4% 4.5% WW 120 217 -45.1% -44.9% -0.2% 563 795 -29.3% -30.6% 1.3% PROCRIT / EPREX US 55 62 -12.8% -12.8% - 223 277 -19.7% -19.7% - Intl 58 66 -13.0% -11.7% -1.3% 256 274 -6.8% -10.1% 3.3% WW 113 129 -12.9% -12.2% -0.7% 479 552 -13.3% -14.9% 1.6% OTHER US 55 85 -35.6% -35.6% - 223 323 -31.0% -31.0% - Intl 143 194 -25.9% -23.8% -2.1% 758 864 -12.2% -15.5% 3.3% WW 198 278 -28.9% -27.4% -1.5% 981 1,186 -17.3% -19.7% 2.4% TOTAL PHARMACEUTICAL US 7,418 7,116 4.2% 4.2% - 27,954 25,735 8.6% 8.6% - Intl 6,870 5,152 33.4% 36.9% -3.5% 24,126 19,837 21.6% 18.8% 2.8% WW 14,288 $ 12,268 16.5% 17.9% -1.4% 52,080 $ 45,572 14.3% 13.1% 1.2% % Change % Change -- 4 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS MEDICAL DEVICES SEGMENT (2) 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency INTERVENTIONAL SOLUTIONS US 483 $ 433 11.6% 11.6% - 1,836 1,452 26.4% 26.4% - Intl 536 460 16.5% 18.8% -2.3% 2,135 1,594 34.0% 29.8% 4.2% WW 1,019 893 14.1% 15.3% -1.2% 3,971 3,046 30.4% 28.2% 2.2% ORTHOPAEDICS US 1,305 1,352 -3.5% -3.5% - 5,126 4,779 7.3% 7.3% - Intl 851 839 1.5% 3.9% -2.4% 3,462 2,984 16.0% 12.1% 3.9% WW 2,155 2,191 -1.6% -0.7% -0.9% 8,588 7,763 10.6% 9.1% 1.5% HIPS US 229 229 0.4% 0.4% - 883 793 11.4% 11.4% - Intl 151 143 4.9% 6.5% -1.6% 602 487 23.6% 18.9% 4.7% WW 380 372 2.1% 2.7% -0.6% 1,485 1,280 16.0% 14.3% 1.7% KNEES US 208 216 -4.2% -4.2% - 787 743 5.9% 5.9% - Intl 135 129 4.6% 6.5% -1.9% 538 427 26.1% 21.7% 4.4% WW 342 345 -0.9% -0.2% -0.7% 1,325 1,170 13.3% 11.7% 1.6% TRAUMA US 467 454 2.8% 2.8% - 1,819 1,648 10.4% 10.4% - Intl 261 268 -2.4% 0.7% -3.1% 1,066 966 10.4% 7.1% 3.3% WW 728 722 0.9% 2.0% -1.1% 2,885 2,614 10.4% 9.2% 1.2% SPINE, SPORTS & OTHER US 401 453 -11.4% -11.4% - 1,637 1,595 2.6% 2.6% - Intl 304 299 2.0% 4.3% -2.3% 1,256 1,104 13.8% 9.9% 3.9% WW 706 752 -6.1% -5.2% -0.9% 2,893 2,699 7.2% 5.6% 1.6% % Change % Change -- 5 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency SURGERY US 986 1,002 -1.7% -1.7% - 3,867 3,249 19.0% 19.0% - Intl 1,527 1,427 7.0% 8.7% -1.7% 5,945 4,983 19.3% 15.6% 3.7% WW 2,513 2,429 3.5% 4.4% -0.9% 9,812 8,232 19.2% 17.0% 2.2% ADVANCED US 457 456 0.5% 0.5% - 1,761 1,535 14.9% 14.9% - Intl 735 660 11.2% 12.6% -1.4% 2,861 2,304 24.1% 20.0% 4.1% WW 1,192 1,116 6.8% 7.6% -0.8% 4,622 3,839 20.4% 18.0% 2.4% GENERAL US 528 546 -3.4% -3.4% - 2,105 1,714 22.7% 22.7% - Intl 793 767 3.4% 5.3% -1.9% 3,085 2,679 15.2% 11.8% 3.4% WW 1,321 1,312 0.6% 1.7% -1.1% 5,190 4,392 18.1% 16.1% 2.0% VISION US 443 397 11.4% 11.4% - 1,857 1,557 19.3% 19.3% - Intl 728 679 7.2% 10.8% -3.6% 2,831 2,362 19.8% 18.8% 1.0% WW 1,171 1,076 8.7% 11.0% -2.3% 4,688 3,919 19.6% 19.0% 0.6% CONTACT LENSES / OTHER US 316 289 9.4% 9.4% - 1,398 1,213 15.2% 15.2% - Intl 518 507 1.9% 5.8% -3.9% 2,043 1,781 14.7% 14.0% 0.7% WW 833 796 4.6% 7.1% -2.5% 3,440 2,994 14.9% 14.5% 0.4% SURGICAL US 126 108 16.8% 16.8% - 459 344 33.5% 33.5% - Intl 211 172 22.9% 25.4% -2.5% 788 581 35.7% 33.3% 2.4% WW 338 280 20.5% 22.1% -1.6% 1,248 925 34.9% 33.4% 1.5% TOTAL MEDICAL DEVICES US 3,216 3,184 1.0% 1.0% - 12,686 11,036 14.9% 14.9% - Intl 3,643 3,405 7.0% 9.3% -2.3% 14,374 11,923 20.6% 17.3% 3.3% WW 6,859 $ 6,589 4.1% 5.3% -1.2% 27,060 $ 22,959 17.9% 16.2% 1.7% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Certain prior year amounts have been reclassified to conform to current year product disclosures (4) Reported as U.S. sales Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. The Company estimates that the inclusion of an additional week in the 2020 fiscal year impacted fiscal fourth quarter 2021 comparative sales growth by approximately -4% and impacted full year fiscal 2021 comparative sales growth by approximately -1%. % Change % Change -- 6 of 6 --